Burzynski Research Institute (BZYR) Cash from Financing Activities (2010 - 2025)
Burzynski Research Institute (BZYR) posted Cash from Financing Activities of $824340.0 for Q4 2025, up 767.57% sequentially from $95017.0 in Q3 2025, and down 7.34% YoY from $889672.0 in Q4 2024.
Burzynski Research Institute (BZYR) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Cash from Financing Activities for 16 years, with the latest figure at $824340.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 7.34% year-over-year to $824340.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $259336.0 (down 79.0% YoY) and the FY2025 annual result came in at $388068.0, down 25.96% from the prior year.
- Cash from Financing Activities climbed to $824340.0 in Q4 2025 per BZYR's latest filing, from $95017.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $889672.0 in Q4 2024 and troughed at -$709138.0 in Q1 2025.
- A 5-year average of $125245.0 and a median of $85492.0 in 2021 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities soared 343.49% in 2024, then tumbled 613.8% in 2025.
- Over 5 years, Cash from Financing Activities stood at $100017.0 in 2021, then sank by 51.99% to $48017.0 in 2022, then jumped by 317.78% to $200605.0 in 2023, then soared by 343.49% to $889672.0 in 2024, then fell by 7.34% to $824340.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $824340.0, $95017.0, and $49117.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 824,340.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 824,340.00 |
| Nov 30, 2025 | 824,340.00 |
| Aug 31, 2025 | 95,017.00 |
| Aug 31, 2025 | 95,017.00 |
| May 31, 2025 | 49,117.00 |
| May 31, 2025 | 49,117.00 |
| Feb 28, 2025 | -709,138.00 |
| Feb 28, 2025 | -709,138.00 |
| Nov 30, 2024 | 889,672.00 |
| Nov 30, 2024 | 889,672.00 |
| Aug 31, 2024 | 149,017.00 |
| Aug 31, 2024 | 149,017.00 |
| May 31, 2024 | 58,517.00 |
| May 31, 2024 | 58,517.00 |
| Feb 29, 2024 | 138,017.00 |
| Feb 29, 2024 | 138,017.00 |
| Nov 30, 2023 | 200,605.00 |
| Nov 30, 2023 | 200,605.00 |
| Aug 31, 2023 | 121,017.00 |
| Aug 31, 2023 | 121,017.00 |